Cargando…

Renal Amyloidosis and Crohn Disease

Background: Secondary amyloidosis, a rare complication of Crohn disease (CD), is triggered by persistent systemic inflammation. Kidney involvement is the most frequent manifestation and is often characterized by nephrotic syndrome and kidney failure. This complication usually appears in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Barahona-Correa, Julián E., Morales, Samuel-David, Andrade-Pérez, Rafael, Hani, Albis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academic Division of Ochsner Clinic Foundation 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442223/
https://www.ncbi.nlm.nih.gov/pubmed/34566512
http://dx.doi.org/10.31486/toj.20.0129
_version_ 1783752968730836992
author Barahona-Correa, Julián E.
Morales, Samuel-David
Andrade-Pérez, Rafael
Hani, Albis
author_facet Barahona-Correa, Julián E.
Morales, Samuel-David
Andrade-Pérez, Rafael
Hani, Albis
author_sort Barahona-Correa, Julián E.
collection PubMed
description Background: Secondary amyloidosis, a rare complication of Crohn disease (CD), is triggered by persistent systemic inflammation. Kidney involvement is the most frequent manifestation and is often characterized by nephrotic syndrome and kidney failure. This complication usually appears in patients with long-standing disease and is associated with increased morbidity and mortality risk. Diagnosis is by microscopic amyloid observation of tissue biopsy, and when the diagnosis is confirmed, the therapeutic objective is disease activity control. Response assessment is challenging because of a lack of reliable biomarkers. Case Report: A 56-year-old male with a long-standing history of CD treated with a tumor necrosis factor-α inhibitor presented with an acute elevation of creatinine in association with clinical and laboratory markers of nephrotic syndrome. Kidney biopsy revealed renal amyloidosis. After treatment adjustment, although a stable creatinine was achieved, the patient had persistent impaired glomerular filtration rate. Conclusion: As a systemic chronic inflammatory disorder, CD may present multisystemic morbidity, for which increased awareness among gastroenterologists is warranted. Renal amyloidosis is an infrequent extraintestinal complication of CD that may lead to chronic kidney impairment. Although evidence-based treatment is lacking, disease activity control is pivotal for management.
format Online
Article
Text
id pubmed-8442223
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Academic Division of Ochsner Clinic Foundation
record_format MEDLINE/PubMed
spelling pubmed-84422232021-09-23 Renal Amyloidosis and Crohn Disease Barahona-Correa, Julián E. Morales, Samuel-David Andrade-Pérez, Rafael Hani, Albis Ochsner J Case Reports and Clinical Observations Background: Secondary amyloidosis, a rare complication of Crohn disease (CD), is triggered by persistent systemic inflammation. Kidney involvement is the most frequent manifestation and is often characterized by nephrotic syndrome and kidney failure. This complication usually appears in patients with long-standing disease and is associated with increased morbidity and mortality risk. Diagnosis is by microscopic amyloid observation of tissue biopsy, and when the diagnosis is confirmed, the therapeutic objective is disease activity control. Response assessment is challenging because of a lack of reliable biomarkers. Case Report: A 56-year-old male with a long-standing history of CD treated with a tumor necrosis factor-α inhibitor presented with an acute elevation of creatinine in association with clinical and laboratory markers of nephrotic syndrome. Kidney biopsy revealed renal amyloidosis. After treatment adjustment, although a stable creatinine was achieved, the patient had persistent impaired glomerular filtration rate. Conclusion: As a systemic chronic inflammatory disorder, CD may present multisystemic morbidity, for which increased awareness among gastroenterologists is warranted. Renal amyloidosis is an infrequent extraintestinal complication of CD that may lead to chronic kidney impairment. Although evidence-based treatment is lacking, disease activity control is pivotal for management. Academic Division of Ochsner Clinic Foundation 2021 2021 /pmc/articles/PMC8442223/ /pubmed/34566512 http://dx.doi.org/10.31486/toj.20.0129 Text en ©2021 by the author(s); Creative Commons Attribution License (CC BY) https://creativecommons.org/licenses/by/4.0/©2021 by the author(s); licensee Ochsner Journal, Ochsner Clinic Foundation, New Orleans, LA. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (creativecommons.org/licenses/by/4.0/legalcode) that permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Case Reports and Clinical Observations
Barahona-Correa, Julián E.
Morales, Samuel-David
Andrade-Pérez, Rafael
Hani, Albis
Renal Amyloidosis and Crohn Disease
title Renal Amyloidosis and Crohn Disease
title_full Renal Amyloidosis and Crohn Disease
title_fullStr Renal Amyloidosis and Crohn Disease
title_full_unstemmed Renal Amyloidosis and Crohn Disease
title_short Renal Amyloidosis and Crohn Disease
title_sort renal amyloidosis and crohn disease
topic Case Reports and Clinical Observations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442223/
https://www.ncbi.nlm.nih.gov/pubmed/34566512
http://dx.doi.org/10.31486/toj.20.0129
work_keys_str_mv AT barahonacorreajuliane renalamyloidosisandcrohndisease
AT moralessamueldavid renalamyloidosisandcrohndisease
AT andradeperezrafael renalamyloidosisandcrohndisease
AT hanialbis renalamyloidosisandcrohndisease